Medical oncologsts discuss the case of a 70-year old woman with synchronous multiple primary lung cancer.
Rudy P. Lackner, MD
Despite a decreasing incidence in the United States, small-cell lung cancer (SCLC) remains a major clinical problem, with approximately 30,000 new cases each year. The diagnosis of SCLC is usually not difficult. The Veterans Administration Lung Study Group (VALSG) staging system is less accurate than the American Joint Committee of Cancer tumor-node-metastasis (TNM) system (7th edition) at predicting survival in SCLC, especially in lower stage disease. Surgery has not played a major part in the management of SCLC, but emerging data suggest that resection may have a role in earlier stage disease. While the frontline treatment of SCLC has not changed significantly in the past decade, newer agents that are currently being investigated provide hope for better treatment of relapsed/refractory disease for the future.
The role of screening in order to
detect lung cancer at an earlier
stage has been widely debated
for the past 4 decades. In this review,
Dr. Mulshine focuses on the current
issues in lung cancer screening in light
of the findings of the International
Early Lung Cancer Action Project
(I-ELCAP) As the article mentions, the
diagnosis of lung cancer is often made
at a stage when the disease is no longer amenable to cure. This is probably the
most important cause for the dismal
outcomes of patients with lung cancer